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AbstrACt
Objective The aim was to investigate the association 
between clinically significant uterine fibroids and preterm 
birth, caesarean section (CS), postpartum haemorrhage 
(PPH), placental abruption, intrauterine growth restriction 
(IUGR) and uterine rupture.
Methods, participants and setting A historical cohort 
study based on data from the Danish National Birth Cohort, 
the Danish National Patient Registry and the Danish 
National Birth Registry (DNBR). The final study population 
consisted of 92 696 pregnancies and was divided into four 
groups for comparison. Group 1: pregnancies of women 
without a fibroid diagnosis code or fibroid operation code; 
group 2: pregnancies of women with a fibroid diagnosis 
code before pregnancy, during pregnancy or up to 1 year 
after delivery, and no fibroid operation code before 
pregnancy; group 3: pregnancies of women with a fibroid 
diagnosis code given more than 1 year after delivery; and 
group 4: pregnancies of women with a fibroid operation 
code given before pregnancy.
results A diagnosis of fibroids before pregnancy yielded 
an increased risk of preterm birth (gestational age (GA) 
≤37 weeks) (OR 2.27 (1.30─3.96)) and extreme preterm 
birth (GA 22+0─27+6 weeks, OR 20.09 (8.04─50.22)). 
The risk of CS was increased (OR 1.83 (1.23─2.72)) 
for women with a fibroid diagnosis code given before 
pregnancy; significantly increased risk of elective CS 
(OR 1.92 (1.11─3.32)), but not acute CS (OR 1.54 
(0.94─2.52)). The risks of PPH, placental abruption or IUGR 
were not increased in any of the groups.
Conclusion We found a strong association between 
clinically significant uterine fibroids and preterm birth, 
and an association between clinically significant uterine 
fibroids and CS. In contrast, no association between 
clinically significant uterine fibroids and PPH, placental 
abruption or IUGR was seen.
IntrOduCtIOn
As many as 10% of pregnant women may 
have uterine fibroids,1 and the incidence is 
likely to be even higher in populations with 
high maternal age and obesity.2 3 Fibroids 
may affect the uterine cavity, the placenta 
and the fetus directly, but may also cause the 
myometrium to be more inflexible and less 
responsive to oxytocin.4 5 Overall, fibroids are 
associated with obstetrical complication rates 
of 10%─40%,6 7 many of which have severe 
consequences. Due to the clinical impact 
on the mother and child, outcomes such as 
preterm birth, caesarean section (CS), post-
partum haemorrhage (PPH), placental abrup-
tion, intrauterine growth restriction (IUGR) 
and uterine rupture have been evaluated in 
relation to uterine fibroids.6–11 Some studies 
showed an association between fibroids and 
preterm birth, CS, PPH and placental abrup-
tion,8 9 12–14 whereas other studies showed no 
association with preterm birth, CS, PPH and 
IUGR.7 13 15
To address these discrepancies, we 
conducted a large historical cohort study of 
unselected pregnant women. We focused on 
women with clinically significant fibroids and 
compared women with a uterine fibroid diag-
nosis code to a reference group of women 
without a uterine fibroid diagnosis code. 
The aim was to investigate the association 
between clinically significant uterine fibroids 
and obstetrical outcomes with a specific focus 
on preterm birth, CS, PPH, placental abrup-
tion, IUGR and uterine rupture. Moreover, 
we analysed the association between myomec-
tomy and the risk of uterine rupture.
MAterIAls And MethOds
This historical cohort study is based on data 
from the Danish National Birth Cohort 
(DNBC), the Danish National Birth Registry 
(DNBR) and the Danish National Patient 
Registry (DNPR).
strengths and limitations of this study
 ► This study explores an area with inconsistent 
evidence.
 ► This study is a large cohort study with data from 
92 696 pregnancies.
 ► Limitations include a low prevalence of uterine fi-
broids and a small number of events.
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study population
The DNBC is a pregnancy cohort consisting of data from 
92 840 women and 101 042 pregnancies. All registered 
pregnancies were included. Enrolment was performed 
in early pregnancy during the period between 1996 and 
2002. Inclusion criteria were the intention to carry a 
pregnancy to term, residency in Denmark, and sufficient 
Danish proficiency to participate in telephone interviews. 
Data were collected by computer- assisted telephone inter-
views twice during pregnancy, and subsequently when 
the children were 6 and 18 months old. The DNBC data 
collection was approved by the Danish National Ethics 
Board. More details about this cohort have previously 
been described in detail.16
The DNPR holds diagnosis and operation codes from 
all inpatients since 1977 and outpatients since 1995. The 
codes are classified according to the International Clas-
sification of Diseases ICD10 since 1994. Diagnosis and 
operation codes regarding fibroids were collected for this 
study.
The DNBR contains information about live births and 
complications of all registered births in Denmark since 
1973.
Selected relevant data from the DNPR and the DNBR 
were linked to data from the DNBC, using the unique 
personal identification number given to all residents in 
Denmark.
data
We collected data on maternal age, height, weight, 
smoking habits, expected date of birth and fertility treat-
ment (regardless of mode of assisted reproductive tech-
nique) from the DNBC. Maternal body mass index (BMI) 
(kg/m2) was calculated based on self- reported prepreg-
nancy weight and height.
Fibroid diagnosis codes (DD25─DD259) and fibroid 
operation codes were collected from the DNPR. Opera-
tion codes were: myomectomy (KLCB10), laparoscopic 
myomectomy (KLCB11), hysteroscopic myomectomy 
(KLCB20), hysteroscopic resection of pathological 
tissue (KLCB22), hysteroscopic excision of pathological 
tissue (KLCB25) and hysteroscopic excision of other 
pathological tissue (KLCB98). We categorised oper-
ation codes into laparoscopic or open myomectomy 
(KLCB10, KLCB11) and hysteroscopic myomectomy 
(KLCB20, KLCB22, KLCB25 and KLCB98). Operation 
codes of the resection and excision of pathological 
tissue were pooled into one group of myomectomy since 
we assumed that many use these codes for hysteroscopic 
myomectomy.
GA, birth weight of the child and data on obstetrical 
outcomes (CS (KMCA10A, KMCA10D, KMCA10E and 
KMCA10B), placental abruption (DO450, DO451, 
DO452, DO453, DO458 and DO459)) and PPH (DO720, 
DO721, DO721A and DO721B) were collected from the 
DNBR.
exposure definition
The study population was divided into four groups for 
comparison. Group 1: pregnancies of women without 
a fibroid diagnosis code or operation code; group 2: 
pregnancies of women with a fibroid diagnosis code 
before pregnancy, during pregnancy or up to 1 year after 
delivery, and no operation code before pregnancy; group 
3: pregnancies of women with a fibroid diagnosis code 
given more than 1 year after delivery; and group 4: preg-
nancies of women with an operation code given before 
pregnancy.
Outcome definition
The outcomes were preterm birth, CS, placental abrup-
tion, PPH, IUGR and uterine rupture.
Preterm birth was defined as delivery at GA 22+0─36+6 
weeks. We divided preterm birth into three categories 
according to the international classifications: moderate 
preterm: GA 34+0─36+6 weeks; very preterm: GA 
28+0─33+6 weeks; and extreme preterm: GA 22+0─27+6 
weeks. Due to the small number of events, we merged the 
groups into clinically relevant binary outcomes: moderate 
preterm: GA 34+0─36+6 weeks and very and extreme 
preterm GA 22+0─33+6 weeks.
CS was categorised as acute (KMCA10A, KMCA10D and 
KMCA10E) or elective (KMCA10B).
Placental abruption was reported under several diag-
nosis codes (DO450, DO451, DO452, DO453, DO458 
and DO458) and pooled into one group.
PPH was defined as bleeding during delivery and up 
to 24 hours postpartum (DO720, DO721, DO721A and 
DO721B).
We followed the international classification of small of 
GA/IUGR as a birth weight below −22% of the expected 
weight at a given GA. This classification was originally 
developed by the 1995 WHO expert committee.17 We 
used a lower limit of −60% based on clinical reasoning; 
all births with an expected birth weight below −60% were 
excluded due to potential misclassification.
Data from the group of women who had a myomectomy 
before pregnancy was used to analyse the association 
between myomectomy and the risk of uterine rupture 
(DO710 and DO711).
data purification
During the data purification, we made some assump-
tions. If a uterine fibroid diagnosis code was given once, 
the woman was categorised as having at least one uterine 
fibroid during the study period, unless she had a fibroid 
operation code. A fibroid diagnosis code given more than 
90 days after a fibroid operation code was interpreted 
as a new uterine fibroid. We assumed the fibroid to be 
present also before pregnancy, if a fibroid diagnosis code 
was given during pregnancy or up to 1- year postpartum, 
and data were included in the fibroid group.
Missing values were identified and analysed. We had 
an 87% complete dataset. Missing values were imputed 
by multiple imputations of multiple variables assuming 
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that values were missing at random. Analyses were made 
before and after imputation.
We identified the potential confounders for each 
outcome based on the directed acyclic graph (DAG).18 
For preterm birth, CS and PPH, we identified maternal 
age and BMI to be possible confounders. For placental 
abruption, we identified maternal age to be a possible 
confounder. For IUGR and uterine rupture, we did not 
identify any possible confounders.
We found that 317 women had a myomectomy before 
pregnancy (205 by hysteroscopy and 112 by laparoscopy).
statistical analyses
A one- way ANOVA was used for comparison of normally 
distributed data such as age. The Kruskal- Wallis test was 
used for comparison of non- normally distributed data 
such as BMI and parity. Smoking habits and fertility treat-
ment were compared using the χ2 test.
We used logistic regression analysis to compare the 
binary outcomes; preterm birth, CS, PPH, placental 
abruption, IUGR and uterine rupture. We adjusted for 
potential confounders identified by DAGs in all analyses 
(maternal age and BMI). By using robust standard errors, 
we accounted for some women being included with more 
than one pregnancy in the analyses.
We found the tests acceptable based on the Hosmer- 
Lemeshow goodness of fit test.
Subgroup analyses of women with a fibroid operation 
code before pregnancy were performed.
We performed stratified analyses for preterm birth 
regarding fertility treatment and multiple pregnancies.
All analyses were performed in STATA V.15.
Patient and public involvement statement
Participants in the DNBC are involved in all research 
based on data from the DNBC. A member of the DNBC 
ambassadors, which is a group of selected participants 
representing all participants, is represented in the DNBC 
reference group. There was no other patient or public 
involvement in this study.
results
Our final study population consisted of 86 323 women 
and 92 696 pregnancies, divided into the four exposure 
groups (figure 1).
Population characteristics for the four exposure groups 
are shown in table 1. The groups did not differ regarding 
BMI, but they differed regarding age, smoking habits, 
parity, multiple pregnancies and proportion of fertility 
treatment.
Preterm birth
The risk of overall preterm birth was increased among 
the group of women who had a fibroid diagnosis code 
before pregnancy (group 2) compared with women 
without a fibroid diagnosis code (group 1), OR 2.3 
(1.30─3.96). The risk of moderately preterm birth was 
not increased, OR 0.6 (0.20─1.96), whereas the risk of 
very preterm, extreme preterm and the pooled group 
of very and extreme preterm birth, was significantly 
increased, OR 4.00 (1.75─9.13), OR 20.1 (8.04─50.22) 
and OR 6.5 (3.51─12.19), respectively. For the group 
of women with a fibroid diagnosis code after pregnancy 
(group 3), the risk of preterm birth was not increased. 
The group of women who had an operation before preg-
nancy (group 4) had an increased risk of overall preterm 
birth of OR 1.8 (1.24─2.65) and very preterm birth OR 
2.8 (1.55─5.22). None delivered extremely preterm 
(table 2).
We stratified accordingly to fertility treatment and 
found an increased risk of extremely preterm birth (OR 
25.6 (7.95─82.43)) among women treated for infer-
tility and among spontaneously pregnant women (OR 
8.4 (1.08─15.76)). The same was applicable for the 
pooled group of very and extreme preterm birth where 
increased risk was found for women with fertility treat-
ment OR 5.6 (2.24─13.85) and spontaneous pregnancy 
OR 4.5 (1.28─15.76). In women with a fibroid diagnosis 
code before pregnancy, the risk of preterm birth was not 
increased in any other groups (table 3).
We also stratified according to singleton pregnancies. 
Among singleton pregnant women with a fibroid diag-
nosis code before pregnancy, we found an increased risk 
of very preterm of OR 3.4 (1.25─9.28); extreme preterm 
of OR 22.3 (8.18─60.92); and the pooled group of very 
and extreme preterm birth of OR 6.1 (2.99─12.51). Apart 
from that, the risk of preterm birth was not increased in 
any other groups (table 3). For multiple pregnancy women 
with a fibroid diagnosis code before pregnancy, we found 
an increased risk of overall preterm of OR 2.2 (1.17─4.05), 
very preterm of OR 4.4 (0.73─26.48), extreme preterm 
of OR 13.0 (1.41─118.77) and pooled very and extreme 
preterm birth of OR 8.5 (1.41─50.93). Apart from that, 
the risk of preterm birth was not increased in any other 
groups (table 3). The risk of preterm birth was increased 
regardless of stratification according to fertility treatment 
(with and without) and type of pregnancy (singleton or 
multiple) (data not shown).
Caesarean section
The overall risk of CS was increased in women with a 
fibroid diagnosis code before pregnancy (group 2), OR 
2.2 (1.50─3.21). The same applied after adjusting for 
age and BMI of OR 1.8 (1.23─2.72). The risk of acute 
CS was not increased in the adjusted analyses, OR 1.5 
(0.94─2.52). The risk of elective CS was increased, OR 
2.6 (1.50─4.41), and the same applied after adjusting 
for age and BMI, OR 1.9 (1.11─3.32). For the group 
of women with an operation code before pregnancy 
(group 4), the risk of CS was also increased; OR 2.6 
(1.85─3.60) for elective CS and OR 1.9 (1.44─2.52) for 
acute CS. The risk of CS was not increased in women 
with a fibroid diagnosis code after pregnancy (group 3) 
(table 2).
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Figure 1 Flowchart of the study population.
PPh, placental abruption and IuGr
The risk of PPH, placental abruption and IUGR was 
not increased in women with a fibroid diagnosis code; 
PPH OR 1.7 (0.70─3.65); placental abruption OR 1.4 
(0.20─10.15); and IUGR OR 1.3 (0.57─2.85) (table 2).
uterine rupture
We found no uterine ruptures in the group with an oper-
ation code before pregnancy (n=317, 112 laparoscopic 
myomectomies and 205 hysteroscopic myomectomies). 
Uterine rupture was diagnosed in 67 of the 91 292 (0.1%) 
women without a fibroid diagnosis code. Two women out 
of the 963 with a fibroid diagnosis code after pregnancy 
(0.21%) were diagnosed with uterine rupture, and no 
women out of 124 (0%) had uterine rupture and a fibroid 
diagnosis code before pregnancy.
dIsCussIOn
Women with a uterine fibroid diagnosis code had a signifi-
cantly higher risk of preterm birth in general, extreme 
preterm birth in particular. The fact that the association 
persisted through all the analyses, irrespective of the 
mode of conception, number of fetuses, age and BMI 
enhances the robustness and significance of our results.
Previous studies that differed in design in terms of 
exposure and outcome found weaker associations. 
A previous systematic review from 2008 reported a 
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Table 1 Population characteristics
No fibroids
group 1
(reference group)
Fibroids before 
pregnancy
no operation
group 2
Fibroids after 
pregnancy
group 3
Fibroid operation 
before pregnancy
group 4
Population, N 91 292 124 963 317
Age, years
Mean (SD)
30 (4.29) 34 (4.15) 32 (3.96) 34 (4.16)
BMI, kg/m2
median (range)
23 (10–64) 23 (16–40) 23 (16–49) 22 (18–35)
Parity median (range) 1 (0–14) 1 (0–3) 1 (0–5) 0 (0–3)
Smoking, % 16.43 11.82 16.04 13.15
Fertility treatment, % 6.32 18.48 9.76 39.39
Multiple pregnancy, % 2.14 4.03 3.95 7.89
cumulative preterm birth rate (before GA 37 weeks) of 
16% among women with fibroids corresponding to an OR 
of 1.5 (1.3─1.7). None of the included studies, however, 
adjusted for potential confounders such as age and BMI.8 
A recent case series from 2018 reported a preterm birth 
rate of 28% in women with uterine fibroids. This study 
did not include a reference group without fibroids, and 
a calculation of the estimated risk was not possible.19 All 
previous studies used different classifications of preterm 
birth, which further complicates comparison. Three 
historical cohort studies all showed an increased risk of 
preterm birth (GA <37 weeks), but they used different 
categorisation regarding GA. Arisoy et al reported an OR 
4.7 (1.9─11.6) for preterm birth <37, OR 4.3 (2.0─13.9) 
for preterm birth <34 weeks, decreasing to OR 3.3 
(0.8─13.4) for preterm birth <32 weeks.20 Blitz et al also 
categorised preterm birth into groups depending on GA 
and found OR 1.61 (1.16─2.23) for preterm birth 34─36 
weeks, OR 2.99 (1.65─5.40) for preterm birth 32─33 
weeks, OR 1.47 (0.59─3.67) for 28─31 weeks and OR 
1.81 (1.49─2.19) for 20─27 weeks.21 In contrast, Lai et al 
found an increased risk of preterm birth with decreasing 
GA; OR 1.70 (1.12─2.58) for 24─34 weeks, OR 1.99 
(1.05─3.75) for 24─28 weeks and OR 2.48 (1.38─4.44) for 
20─27 weeks.22 All three cohort studies included women 
who had undergone routine second- trimester obstetrical 
ultrasound, which was the basis for inclusion into the 
exposure or control group. Women in our cohort study 
were included based on a fibroid diagnosis code and we 
assume that many clinical insignificant fibroids with no 
symptoms were never diagnosed. Therefore, women in 
our cohort are likely to be different from women with 
fibroids diagnosed by routine ultrasound in pregnancy.
In line with previous studies, women with a fibroid diag-
nosis code had an increased risk of elective CS. A review 
from 2016 based on 13 studies reported a cumulative CS 
frequency of 49% corresponding to an unadjusted OR of 
3.7 (3.5─3.9).23 These findings are in line with the clin-
ical guidelines of elective CS if the uterine fibroids are 
evaluated to infer a risk of mechanical obstruction or 
malpresentation. Further, we found that women with a 
fibroid diagnosis code intended for vaginal delivery had 
the same risk of acute CS as women without a fibroid diag-
nosis code.
With regard to the risk of PPH, placental abruption 
or IUGR, we found no differences between groups. In 
contrast, a review from 2016, based on historical cohort 
studies, and a systematic review from 2008, suggested an 
increased risk of all three outcomes.23 However, other 
studies, which for different reasons were not included 
in the systematic review, are consistent with our find-
ings.9 13 20 22 24
We found no uterine ruptures following laparoscopic 
myomectomy (n=112). The risk of uterine rupture 
following laparoscopic myomectomy has been compared 
with the risk following uterine surgery such as CS,23 25 26 and 
some authors have reported an increased risk of uterine 
rupture after myomectomy.27 Based on clinical reasoning 
it is believed that surgical skills and techniques such as 
the use of bipolar diathermy, and timespan from oper-
ation to pregnancy are essential factors for the risk of 
uterine rupture after myomectomy. Our study did not 
allow the analysis for these factors. In Denmark, complex 
laparoscopic myomectomy is preferentially performed 
by experienced surgeons and 6 months from operation 
to pregnancy is recommended. Both factors are likely to 
have contributed to the low rate of uterine rupture found 
in our study.
In a review from 2016, it was suggested that fibroid 
treatment minimises the risk of adverse negative obstet-
rical outcomes. However, they also concluded that more 
clinical studies are needed to draw firm conclusions as 
findings are still inconsistent.28 In the present study, the 
risk of preterm birth decreased whereas the risk of CS 
increased after myomectomy compared with the risks 
among women with untreated uterine fibroids. Our 
results contribute to the overall discussion about treat-
ment prior to pregnancy, however, more studies are 
required. A randomised controlled trial, which would 
be optimal for firm conclusions, is not possible due to 
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ethical considerations. At best, a large cohort study with 
detailed exposure and outcome information can give 
further information.
lIMItAtIOns
Our results are based on retrospective data, and the 
number of events was small despite the large size of the 
cohort. We found a low prevalence of uterine fibroid 
diagnosis codes in our study population compared 
with previous reports.29 It might indicate that women 
participating in DNBC consisted of a selected group of 
women.30 Our results cannot be used as an indicator of 
prevalence or incidence in the general population, but it 
is important to notice, that data are fully valid for analyses 
of associations.31
Our exposure registration was based on clinical diag-
nosis coding, which may be incorrect or lacking due 
to various work- related distractions and a variable indi-
vidual interpretation of clinical cases, leading to exposure 
misclassification. The low prevalence of uterine fibroids 
in our study population is likely to be a result of underre-
porting. A potential bias will lead towards exposed women 
being categorised as unexposed, and hence attenuation of 
the association between exposure (uterine fibroids) and 
outcomes.32 Since the potential underreporting is inde-
pendent of the outcome due to the prospective nature of 
data collection in a cohort study, a potential misclassifica-
tion could lead to non- differential information bias.
Further, we found that some women had an operation 
code, but no diagnosis code, substantiating the hypoth-
esis of risk of exposure misclassification. In Denmark, 
operation codes are more closely connected to hospital 
budgets than clinical diagnosis codes. A detailed vali-
dation of data would most likely have solved discrepan-
cies, but we did not have the possibility to validate the 
data from the DNPR, and we relied on previous studies, 
showing that reproductive gynaecological coding in the 
DNPR is generally valid and suitable for clinical quality 
control.33
Risk of misclassification related to the operation codes 
could have been cleared by postoperative histological 
diagnoses. As these data were not available, we minimised 
the risk by ensuring that none of the women in our expo-
sure group had a diagnoses code for other uterine pathol-
ogies such as adenomyosis or polyps.
The DNBC mainly consists of white women with middle 
or high social status30 and since uterine fibroids have 
different pathophysiology for example Afro- American 
and Caucasian woman,34 our results can only reasonably 
be applied to the Scandinavian population.
A short cervix in early pregnancy has been associated 
with uterine fibroids and may represent part of the mech-
anism behind the risk of preterm birth among women 
with uterine fibroids.7 21 Unfortunately, we did not have 
the opportunity to investigate the contribution of cervical 
length on preterm birth due to the lack of a specific diag-
nosis code.
COnClusIOns
The present study, including 92 696 pregnancies, found 
a strong association between a uterine fibroid diagnosis 
and the risk of preterm birth in general and extreme 
preterm birth in particular. We suggest that future clin-
ical studies focus on the relationship between obstetrical 
outcomes and fibroids in terms of anatomical location, 
growth throughout pregnancy and cervical length.
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